DUBLIN--(BUSINESS WIRE)--The "Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Kv1.3 Potassium Channel Blockers - Pipeline ...

According to WHO, there are some 130 million diagnosed diabetics in the world, a figure that is predicted to increase to 300 million by 2025. The market for diabetes therapeutics is also rising with ...

Anu Tyagi, Tofayel Ahmed, Shi Jian, Saumya Bajaj, Seow Theng Ong, Stephanie Shee Min Goay, Yue Zhao, Igor Vorobyov, Changlin Tian, K. George Chandy, Shashi Bhushan Proceedings of the National Academy ...

Target of the Month, (from TherapeuticAdvances, August, 2003): As research into ion channels continues to identify novel targets for multiple and diverse diseases, therapeutic successes surrounding ...

Autoreactive memory T lymphocytes are implicated in the pathogenesis of autoimmune diseases. Here we demonstrate that disease-associated autoreactive T cells from patients with type-1 diabetes ...

GHENT, Belgium, 19 June 2014 - Ablynx [Euronext Brussels: ABLX] today announced that it will present pre-clinical proof-of-concept data on its proprietary anti-Kv1.3 Nanobody® at two upcoming leading ...

Researchers have investigated the role of the voltage-dependent potassium channel Kv1.3 in vivo in a murine model of ethanol-exposed alcohol-related liver disease (ALD).

Kv1.3 is a voltage-gated potassium channel that plays a crucial role in neuroinflammation and neurodegeneration in Parkinson’s disease and other disorders. Preclinical studies have shown that Kv1.3 ...

DUBLIN--(BUSINESS WIRE)--The "Kv1.3 Potassium Channel Blockers -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. 'Kv1.3 Potassium Channel Blockers - Pipeline ...